Axiomer Investor Call

Event info


ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly. 

The live and archived webcast of this presentation will be accessible through this webcast link. The archived webcast will be available for approximately 30 days following the presentation date.

Download the presentation

About Axiomer®

ProQR is pioneering a next-generation RNA editing technology called Axiomer®, which could potentially yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, induce single nucleotide changes to RNA in a highly specific and targeted way using the cell’s own molecular machinery. The Axiomer® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G). There are over 20,000 G to A mutations known to cause human disease that could be reversed using this novel technology.